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ABSTRACT This real-world study compared the effectiveness of triple therapy (TT; long-acting
muscarinic antagonists (LAMAs)/long-acting inhaled β-agonists (LABAs)/inhaled corticosteroids (ICSs))
versus dual bronchodilation (DB; LAMAs/LABAs) among patients with frequently exacerbating COPD. A
matched historical cohort study was conducted using United Kingdom primary care data. Patients with
COPD aged ⩾40 years with a history of smoking were included if they initiated TT or DB from no
maintenance/LAMA therapy and had two or more exacerbations in the preceding year. The primary
outcome was time to first COPD exacerbation. Secondary outcomes included time to treatment failure,
first acute respiratory event, and first acute oral corticosteroid (OCS) course. Potential treatment effect
modifiers were investigated. In 1647 matched patients, initiation of TT reduced exacerbation risk (adjusted
hazard ratio (HR) 0.87, 95% CI 0.76–0.99), risk of acute respiratory event (HR 0.74, 95% CI 0.66–0.84)
and treatment failure (HR 0.83, 95% CI 0.73–0.95) compared with DB. Risk reduction for acute respiratory
events was greater for patients with higher rates of previous exacerbations. At baseline blood eosinophil
counts (BECs) ⩾ 0.35×109 cells·L−1, TT was associated with lower risk of OCS prescriptions than DB. This
study provides real-life evidence of TT being more effective in reducing exacerbation risk than DB, which
became more accentuated with increasing BEC and previous exacerbation rate.
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Introduction
Chronic obstructive pulmonary disease (COPD) is characterised by persistent and progressive airflow
limitation with a proportion of patients suffering from exacerbations of the disease [1]. The mainstay of
therapeutic management in COPD are long-acting inhaled bronchodilators, either long-acting muscarinic
antagonists (LAMAs) or long-acting inhaled β-agonists (LABAs), with the primary aim of reducing
symptoms and exacerbations while improving wellbeing [2]. A combination of LAMAs/LABAs is
recommended in patients where disease control is not satisfactory using long-acting bronchodilator
monotherapy, and inhaled corticosteroids (ICSs) can be added for triple therapy (TT; ICS plus LAMA
plus LABA) for those with persisting exacerbations [2]. However, ICS use has been associated with an
increased risk of adverse events, including pneumonia [3], bone fracture, and skin thinning/easy bruising
[4]. ICS therapy is widely prescribed in clinical practice in patients with COPD [5, 6].
TT has been shown to be more effective than an ICS/LABA combination for the treatment of COPD [7,
8]. Recent randomised controlled clinical trials (RCTs) support the efficacy of TT compared with dual
bronchodilation (DB) with LAMAs/LABAs in selected populations [9, 10]. In addition, a higher blood
eosinophil count (BEC) in patients with COPD has been associated with an increased benefit from ICSs in
terms of exacerbation reduction [11]. There has been a call for representative, longer-term studies to
determine the potential benefits of TT versus DB therapy, to improve the evidence which informs real-life
prescribing decisions [12, 13]. This study aims to compare the real-world effectiveness of TT versus DB in
the treatment of patients with frequently exacerbating COPD and to explore the potential heterogeneity of
the effectiveness driven by patient and therapy characteristics.
Methods
Study design and data sources
A matched historical cohort study was conducted on patients with COPD in the United Kingdom (UK).
Data were extracted from two databases: the Optimum Patient Care Research Database (OPCRD; https://
opcrd.co.uk/) and the Clinical Practice Research Datalink (CPRD; www.cprd.com/). The OPCRD contains
anonymised, longitudinal medical record data for over 5 million patients from 650 primary care practices.
It is a high-quality data source used regularly in clinical, epidemiological, and pharmaceutical research [14, 15].
The CPRD contains anonymised primary care data for 5 million patients from >600 general practices in
the UK. The overlap in practices covered by these two databases is <5%. To maximise the sample size,
data were extracted from both the OPCRD and CPRD for patients who stepped-up between 2003 and
2017 from no prior maintenance therapy or LAMA monotherapy for COPD, to either DB or TT. Data
were combined, and duplicates were removed. The data extracted included demographic and clinical
characteristics, prescriptions, and data on comorbidities.
The quality of some data is driven by the Quality and Outcomes Framework (QOF) in the UK including
diagnostic and annual spirometry and mMRC recording [16]. The clinical data are mostly recorded using
read codes, and the QOF requires spirometry to confirm the COPD diagnostic read codes in the UK. The
diagnosis of COPD in CPRD has been validated [17].
Index date: date of therapy
Outcome period
Triple therapy arm (LAMA/LABA/ICS)
Dual therapy arm (LAMA/LABA)
Baseline period
(1 year)
Other inclusion criteria:
  ≥40 years
  Diagnostic read code for COPD
  History of smoking
  ≥1 year of continuous practice data prior to 
    the index date
  Step-up from no maintenance therapy or 
    LAMA only
≥2 COPD exacerbations
FIGURE 1 Study design. ICS: inhaled corticosteroid; LABA: long-acting inhaled β-agonist; LAMA: long-acting
muscarinic antagonist.
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This study included a 1-year baseline period preceding the index date, and an outcome period after the
index date, ending at the last date of data extraction or patient deregistration (figure 1). The index date
was defined as the date of therapy step-up. Patients were divided into the following two cohorts (exposure
groups): patients initiating TT (LAMAs/LABAs/ICSs) and patients initiating DB therapy (LAMAs/LABAs)
without ICSs, both from prior no maintenance therapy or LAMA monotherapy. Patients on all inhaler
combinations of the treatments under study were included. To avoid the inclusion of patients under DB
treatment who recently stopped ICSs, patients were excluded if they had been treated with ICSs in the
12 months prior to the index date. This exclusion was conducted because stepping down ICSs could
potentially bias the results in favour of TT.
Study population
Patients who met the following criteria were eligible for inclusion: a diagnostic read code for COPD, aged
⩾40 years, history of smoking, had ⩾1 year of continuous data prior to the index date (baseline year), and
⩾2 moderate/severe exacerbations in the baseline year. The exclusion criteria included active asthma at or
after the index date (defined as ⩾1 diagnostic read code for asthma or ⩾1 asthma monitoring or review
read code recorded on or after the index date), a diagnostic code for asthma–COPD overlap syndrome,
and a diagnostic code ever for other chronic lower respiratory conditions. All code lists are available from
the study authors.
Study outcomes
The primary outcome was the time to first COPD exacerbation to avoid the exclusion of patients who were
lost to follow-up from the analyses. Secondary outcomes included time to first acute respiratory event,
time to treatment failure, time to first acute oral corticosteroid (OCS) course, time to first antibiotic
prescription with evidence of a lower respiratory primary care consultation, modified Medical Research
Council (mMRC) dyspnoea score within 18 months after the index date, time to first pneumonia
diagnosis, and the number of occurrences in the first year of the outcome period of the following:
exacerbations, acute OCS courses, antibiotic prescriptions with evidence of a lower respiratory primary
care consultation and acute respiratory events. Definition of study outcomes are listed in table 1.
TABLE 1 Study outcomes and definitions
Primary
1) Time to first exacerbation
Respiratory-related hospital attendance/admission AND/OR
Respiratory-related emergency room attendance AND/OR
Prescription of acute OCS course AND/OR
Antibiotics prescribed with evidence of lower respiratory consultation on the same day
Secondary
2) Time to first acute respiratory event
Respiratory-related consultation, not for annual monitoring review
3) Time to treatment failure
Prescription of additional chronic therapy (theophylline or other methylxanthines); maintenance OCS;
PDE4 inhibitor; macrolides (e.g. azithromycin, erythromycin); mucolytics (e.g. carbocysteine,
N-acetylcysteine); LTRA (nedocromil) AND/OR
An exacerbation (as defined above)
4) Time to first acute OCS course
5) Time to first antibiotics prescription with evidence of lower respiratory consultation, to avoid
misclassification of antibiotics being prescribed for another reason [18]
Number of occurrences in the first 1-year outcome period of:
6) Exacerbations
7) Acute OCS courses
8) Antibiotic prescriptions with evidence of lower respiratory consultation
9) Acute respiratory events
10) mMRC score within 18 months after index date; ⩾2 versus <2
11) Time to first pneumonia diagnosis
Chest radiography AND/OR
Diagnostic code
OCS: oral corticosteroid; PDE: phosphodiesterase; LTRA: leukotriene receptor antagonist; mMRC: modified
Medical Research Council dyspnoea scale.
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Data analysis
All data were analysed using Stata MP/6 version 15.1 (StataCorp, College Station, TX, USA). The number
of clinical events or measurements occurring at the index date were included in the baseline
characterisation, however, prescriptions of drugs at the index date were not included. Standardised mean
difference (SMD) was used to quantify differences in both continuous and categorical variables between
the treatment cohorts at baseline. An SMD ⩽10% indicated sufficient balance between treatment cohorts.
The p-values were also reported for differences at baseline using Pearson’s Chi-squared test for categorical
variables and the Kruskal–Wallis equality-of-populations rank test for variables on a continuous or ordinal
scale. Binary and categorical variables were summarised with frequencies and percentages, whereas
distributions and descriptive statistics of central tendency (medians and means) and dispersion (SD and
interquartile range) were produced for quantitative variables.
Patients in the DB and TT cohorts were propensity score matched to account for potential biases, such as
indication bias, where different treatment combinations could be selected for patients with different
disease severity. A propensity score was created using a logistic regression model including all baseline
variables [19, 20]. The cohorts were matched 1 to 3 without replacement using nearest neighbour calliper
matching. After matching, the SMD was recalculated to verify the accuracy of the propensity score model.
To assess the robustness of findings with regards to potential restriction of the study population due to the
matching, the inverse probability of treatment weighting (IPTW) approach, which uses all available
patients, was used for sensitivity analyses.
The follow-up duration was summarised and the unadjusted incidence rate for each outcome per
patient-year of follow-up time was calculated for the treatment cohorts. To compare the incidence rate per
outcome between the treatment cohorts, unadjusted incidence rate ratios (IRRs) with 95% confidence
intervals (CI) were calculated.
The proportion of patients improving, remaining unchanged, and worsening from the 1-year baseline to
the first year of the outcome period in terms of the number of outcome events of interest was calculated,
and a number needed to benefit (NNB) was derived from these values. NNB provides a measure for the
benefit of a treatment while also taking account of the patients who remained unchanged and worsened
due to the treatment [21]. For this specific analysis, only patients with ⩾1 year of follow-up were included.
The start of follow-up for each patient was their index date. The end of follow-up was defined as the earliest
date at which the patient developed the outcome of interest, transferred out of the practice, died, or the date
of the practice’s last data collection. A time-to-event analysis was performed to estimate the association
between treatment and time to first outcome event with right censoring at loss to follow-up. Stratified Cox
regression was used to estimate hazard ratios (HRs) of the treatment effect for each outcome, adjusted for any
residual confounders following matching. Holm’s method was used to indicate which of the 10 secondary
outcomes were significant after adjustment for multiple testing [22]. The proportional hazard assumption was
evaluated visually by means of a log–log plot of survival. Conditional negative binomial regression was used
to compare count outcomes, and conditional logistic regression was used to compare binary outcomes.
Residual confounders were selected by assessing their bias potential, the relative change in the coefficient
resulting from their addition to the model predicting the outcome of interest. A coefficient change of ⩾2%
designated the variable as a confounder. See supplementary table 1 for the covariates identified as showing
residual confounding and used to adjust for in the multivariable models in the matched cohort. A p-value
<0.05 was considered statistically significant. An intention-to-treat design was used, thus allowing patients in
the two treatment cohorts to change their therapy during follow-up, without being censored or otherwise
removed from the analyses. A sensitivity analysis excluding patients with a history of asthma prior to the
index date was carried out post hoc to confirm that any effect seen was not due to asthma.
To assess the effect modification, an interaction term between treatment and candidate modifiers (number
of exacerbations, most recent BEC, level of airflow limitation, GOLD risk group, and number of
nonrespiratory drugs prescribed in baseline year) was added to the models adjusted for confounders. For
the time to pneumonia diagnosis, the effect modification could not be assessed due to a small number of
events. Results were presented for the other 10 outcomes. Holm’s method was used to indicate which
outcomes were significant after adjustment for multiple testing for each candidate modifier separately (10
tests). Patients were categorised into a GOLD risk group based on their mMRC score. We selected the
mMRC score instead of the COPD Assessment Test score as we previously observed mMRC to be more
conservative in classifying patients into GOLD risk groups [23].
Results
There were 1181 patients with 2864 patient-years of follow-up in the TT arm and 466 patients with 1090
patient-years of follow-up in the DB arm. For a flow diagram of patient selection see figure 2. The
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demographic and clinical characteristics of matched patients are presented in table 2 and supplementary
table 2. Over 90% (72/77) characteristics were well balanced between the matched cohorts, indicated by
SMD <10%. The mean age of patients in both treatment cohorts was 69 years and about half were male.
Nearly half of the patients had an mMRC score between 2–4, corresponding to GOLD group D. The
number of nonreliever drugs taken by patients at baseline is presented in supplementary table 3. Following
matching, the number of nonreliever drugs were balanced between the TT arm and the DB arm. Almost
half of the DB-initiating patients did not change their therapy for the duration of their follow-up; this was
the case for 58% of TT initiators (Supplementary Table 4). See Supplementary Table 5 for baseline
characteristics of the unmatched cohorts.
Patients in both arms showed great improvement in the number of exacerbations, acute respiratory events,
acute OCS courses, and antibiotics courses from the baseline 1-year period to the first year of follow-up
period. The proportion of patients who showed an improvement in the number of exacerbations, acute
respiratory events, and acute OCS courses were higher for those initiating TT compared with patients
initiating DB (table 3). The proportion of patients worsening was mostly lower for TT. This resulted in the
number of patients needed to benefit from TT ranging 10–21 for these outcomes, and higher for the number
of antibiotics courses (134). These statistics were similar to the unmatched cohort (data not shown).
Between 2003 and 2017, 176 927 patients in
OPCRD and 122 176 patients in CPRD had a 
COPD diagnostic code
Patients who initiated LAMA/LABA or triple therapy
and were not treated with this in baseline year
OPCRD
LAMA/LABA: 2276
Triple therapy: 31 194
CPRD
LAMA/LABA: 4198
Triple therapy: 38 286
OPCRD
LAMA/LABA: 142
Triple therapy: 1122
CPRD
LAMA/LABA: 351
Triple therapy: 1497
LAMA/LABA
493 records
492 patients
Triple therapy
2619 records
2603 patients
LAMA/LABA
466 patients
Triple therapy
1181 patients
Propensity score matching (1:3)
OPCRD and CPRD combined
Final unmatched (records)
Excluded (n=73 562)
<1 year of continuous practice
  data prior to index date (n=7255)
Age <40 years (n=181)
No recorded history of smoking
  (n=2707)
Diagnostic code for other chronic
  lower respiratory condition (n=6466)
Diagnostic code for asthma–COPD 
  overlap syndrome (n=26)
Active asthma (n=13 685)
Duplicate (n=1173)
Age unknown (n=27)
Prior maintenance therapy other
  than LAMA only (n=27 651)
<2 exacerbations in baseline (n=14 391)
FIGURE 2 Flow diagram of patient selection. CPRD: Clinical Practice Research Datalink; LABA: long-acting
inhaled β-agonist; LAMA: long-acting muscarinic antagonist; OPCRD: Optimum Patient Care Research
Database.
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TABLE 2 Patient baseline characterisation, matched
LAMA/LABA (n=466) Triple therapy
(n=1181)
p-value SMD
Age years 69.2±10.7/70.0 (15.0) 69.4±10.2/69.0 (14.0) 0.672 2.0
⩾40–<60 years 92 (19.7%) 194 (16.4%) 0.278 6.8
⩾60–<80 years 295 (63.3%) 778 (65.9%)
⩾80 years 79 (17.0%) 209 (17.7%)
Males 233 (50.0%) 603 (51.1%) 0.699 2.1
Index year 2013.2±3.4/2014.0 (5.0) 2012.5±2.9/2013.0 (4.0) <0.001 21.8
BMI n (% nonmissing) 463 (99.4%) 1167 (98.8%) 0.506 7.5
<18.5 kg·m−2 22 (4.8%) 69 (5.9%)
⩾18.5–<25 kg·m−2 145 (31.3%) 397 (34.0%)
⩾25–<30 kg·m−2 159 (34.3%) 376 (32.2%)
⩾30 kg·m−2 137 (29.6%) 325 (27.8%)
Current smoker
No 256 (54.9%) 653 (55.3%) 0.896 0.7
Yes 210 (45.1%) 528 (44.7%)
Asthma diagnosis, ever 38 (8.2%) 153 (13.0%) 0.006 15.7
Charlson Comorbidity Index
⩽1 333 (71.5%) 845 (71.5%) 0.999 0.1
2–4 76 (16.3%) 190 (16.1%)
5–9 26 (5.6%) 67 (5.7%)
⩾10 31 (6.7%) 79 (6.7%)
Blood eosinophil count n
(% nonmissing)
391 (83.9%) 983 (83.2%) 0.808 2.2
<0.05×109 cells per L 8 (2.0%) 31 (3.2%)
0.05–0.14×109 cells per L 110 (28.1%) 267 (27.2%)
0.15–0.24×109 cells per L 110 (28.1%) 281 (28.6%)
0.25–0.34×109 cells per L 80 (20.5%) 187 (19.0%)
0.3–0.44×109 cells per L 27 (6.9%) 86 (8.7%)
0.4–0.54×109 cells per L 23 (5.9%) 54 (5.5%)
0.5–0.64×109 cells per L 10 (2.6%) 30 (3.1%)
⩾0.65×109 cells per L 23 (5.9%) 47 (4.8%)
SABA prescriptions
0 63 (13.5%) 237 (20.1%) 0.021 8.1
1–2 103 (22.1%) 235 (19.9%)
3–5 100 (21.5%) 220 (18.6%)
6–9 108 (23.2%) 241 (20.4%)
⩾10 92 (19.7%) 248 (21.0%)
Salbutamol-equivalent average daily
SABA dose
0 μg 63 (13.5%) 237 (20.1%) 0.033 8.9
1–100 μg 48 (10.3%) 110 (9.3%)
101–200 μg 83 (17.8%) 189 (16.0%)
201–300 μg 58 (12.4%) 110 (9.3%)
301–400 μg 41 (8.8%) 102 (8.6%)
>400 μg 173 (37.1%) 433 (36.7%)
SAMA prescriptions
0 415 (89.1%) 1044 (88.4%) 0.982 1.6
1 11 (2.4%) 31 (2.6%)
2 7 (1.5%) 19 (1.6%)
⩾3 33 (7.1%) 87 (7.4%)
LAMA prescriptions
0 139 (29.8%) 343 (29.0%) 0.001 13.9
1–3 89 (19.1%) 213 (18.0%)
4–6 81 (17.4%) 135 (11.4%)
7–9 56 (12.0%) 124 (10.5%)
10–12 63 (13.5%) 216 (18.3%)
⩾13 38 (8.2%) 150 (12.7%)
Average daily OCS dose
<2.5 mg 379 (81.3%) 983 (83.2%) 0.433 1.2
⩾2.5–<5 mg 52 (11.2%) 112 (9.5%)
Continued
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Unadjusted IRRs
For the primary outcome (time to first exacerbation), the average duration of follow-up per patient was 0.74
and 0.87 years in the TT and DB arms, respectively. The incidence rate of a first exacerbation in the outcome
period was lower in the TT arm (0.79/patient-year) compared with the DB arm (0.91), equating to an
unadjusted IRR of 0.87 (95% CI 0.76–0.99; table 4). The IRRs for time to an acute respiratory event and
treatment failure were also in favour of TT, as were those for time until first acute OCS course and first
antibiotics course, although the differences for the latter two outcomes were not statistically significant (table 4).
TABLE 2 Continued
LAMA/LABA (n=466) Triple therapy
(n=1181)
p-value SMD
⩾5–<7.5 mg 18 (3.9%) 31 (2.6%)
⩾7.5 mg 16 (3.4%) 49 (4.1%)
5 mg 0 (0.0%) 4 (0.3%)
6 mg 1 (0.2%) 2 (0.2%)
Acute respiratory events in baseline
year#
0 22 (4.7%) 53 (4.5%) 0.797 5.0
1 48 (10.3%) 116 (9.8%)
2 90 (19.3%) 200 (16.9%)
3 96 (20.6%) 256 (21.7%)
⩾4 210 (45.1%) 556 (47.1%)
Exacerbations in baseline year#
2 287 (61.6%) 698 (59.1%) 0.718 3.4
3 105 (22.5%) 284 (24.0%)
4 34 (7.3%) 101 (8.6%)
⩾5 40 (8.6%) 98 (8.3%)
Acute OCS courses in baseline
year#
0 95 (20.4%) 234 (19.8%) 0.700 1.7
1 117 (25.1%) 328 (27.8%)
⩾2 254 (54.5%) 619 (52.4%)
Antibiotic courses in baseline year#
0 80 (17.2%) 202 (17.1%) 0.627 2.9
1 115 (24.7%) 296 (25.1%)
2 183 (39.3%) 435 (36.8%)
3 63 (13.5%) 165 (14.0%)
4 13 (2.8%) 55 (4.7%)
⩾5 12 (2.6%) 28 (2.4%)
GOLD severity (% nonmissing) 373 (80.0%) 957 (81.0%) 0.394 8.0
Mild, FEV1 >80% predicted 44 (11.8%) 105 (11.0%)
Moderate, FEV1 50–80% predicted 190 (50.9%) 447 (46.7%)
Severe, FEV1 30–50% predicted 94 (25.2%) 281 (29.4%)
Very severe, FEV1 <30% predicted 45 (12.1%) 124 (13.0%)
GOLD risk group¶ n (% nonmissing) 389 (83.5%) 976 (82.6%) 0.187 7.9
C 236 (60.7%) 554 (56.8%)
D 153 (39.3%) 422 (43.2%)
mMRC score n (% nonmissing) 389 (83.5%) 976 (82.6%) 0.671 5.7
0, not troubled by breathlessness 37 (9.5%) 98 (10.0%)
1, short of breath 199 (51.2%) 456 (46.7%)
2, slower in walking 96 (24.7%) 266 (27.3%)
3, stopping for breath 49 (12.6%) 131 (13.4%)
4, too breathless to leave the house 8 (2.1%) 25 (2.6%)
Data are presented as mean±SD/median (interquartile range) unless otherwise stated. LAMA: long-acting
muscarinic antagonist; LABA: long-acting inhaled β-agonist; SMD: standardised mean difference; IQR:
interquartile range; BMI: body mass index; SABA: short-acting inhaled β-agonist; SAMA: short-acting
muscarinic antagonist; LAMA: long-acting muscarinic antagonist; OCS: oral corticosteroid; GOLD: Global
Initiative for Chronic Obstructive Lung Disease; FEV1: forced expiratory volume in 1 s; mMRC: modified
Medical Research Council dyspnoea scale. #includes the index date; ¶: symptom and risk based. p-values
are for the Kruskal–Wallis equality-of-populations rank test or Pearson’s Chi-squared test of independent
categories, where appropriate.
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Multivariable outcome models
The effect sizes of TT versus DB for the outcomes of interest are presented in table 5. All time-to-event
adjusted analyses results were in favour of TT. A significantly reduced risk in favour of TT was seen for
the primary outcome of first exacerbation (HR 0.87, 95% CI 0.76–0.99). Among the secondary outcomes,
first acute respiratory event (HR 0.74, 95% CI 0.66–0.84) and treatment failure (HR 0.83, 95% CI
0.73–0.95) were significantly in favour of TT after statistical adjustment and correction for multiple testing.
A reduced risk in favour of TT was also seen for first acute OCS course and first antibiotics course, but
these did not reach significance. Results of the conditional negative binomial regression showed
significantly lower acute OCS courses rate (rate ratio (RR) 0.80, 95% CI 0.66–0.98) and acute respiratory
events rate (RR 0.79, 95% CI 0.70–0.90) in the TT group. The effect sizes in the sensitivity analyses using
IPTW were similar to the time-to-event models (data not shown) as were the results after excluding
patients with a history of asthma (for some outcomes a slightly stronger effect was seen; supplementary
table 6).
Effect modification
The results presented below are based on the investigation of the effect of the number of previous
exacerbations and baseline BEC as continuous variables. On visual inspection, the results using the
categorical representation of these potential effect modifiers did not show a meaningful difference with the
TABLE 3 Number of patients improving or worsening from baseline to the first outcome year, matched
Improved Unchanged Worsened NNB
LAMA/LABA Triple therapy LAMA/LABA Triple therapy LAMA/LABA Triple therapy
Exacerbations 225 (73.5%) 651 (78.2%) 41 (13.4%) 96 (11.5%) 40 (13.1%) 85 (10.2%) 21
Acute respiratory events 173 (56.5%) 550 (66.1%) 51 (16.7%) 123 (14.8%) 82 (26.8%) 159 (19.1%) 10
Acute OCS courses 158 (51.6%) 494 (59.4%) 98 (32.0%) 213 (25.6%) 50 (16.3%) 125 (15.0%) 15
Antibiotics courses 193 (63.1%) 523 (62.9%) 72 (23.5%) 218 (26.2%) 41 (13.4%) 91 (10.9%) 134
mMRC score 32 (16.7%) 32 (6.1%) 101 (52.6%) 264 (50.2%) 59 (30.7%) 163 (31.0%)
LAMA: long-acting muscarinic antagonist; LABA: long-acting inhaled β-agonist; NNB: number needed for one patient to benefit from triple
therapy [21]; OCS: oral corticosteroid; mMRC: modified Medical Research Council dyspnoea scale.
TABLE 4 Unadjusted incidence rate (IR) ratios for time-to-event outcomes, by matched treatment cohort
Patients and follow-up years per cohort Events per cohort Comparison
Cohort Patients Total
years
Mean±SD
years#
Events IR per
patient-year
IR difference (95% CI) IR ratio (95% CI)
Exacerbation (primary
outcome)
TT 1181 1022 0.74±0.88 812 0.794 −0.119 (−0.233–−0.004) 0.870 (0.763–0.994)
DB 466 346 0.87±1.04 316 0.913
Acute respiratory
event (secondary
outcome)
TT 1181 592 0.37±0.53 957 1.618 −0.560 (−0.803–−0.316) 0.743 (0.659–0.840)
DB 466 172 0.50±0.73 374 2.178
Treatment failure
(secondary
outcome)
TT 1181 867 0.60±0.77 874 1.008 −0.227 (−0.374–−0.080) 0.816 (0.720–0.927)
DB 466 278 0.73±0.92 343 1.236
Acute OCS course
(secondary
outcome)
TT 1181 1367 1.02±1.21 683 0.499 −0.058 (−0.134–0.019) 0.896 (0.777–1.037)
DB 466 477 1.16±1.28 266 0.557
Antibiotics course
(secondary
outcome)
TT 1181 1341 1.00±1.17 659 0.491 −0.052 (−0.129–0.025) 0.904 (0.781–1.049)
DB 466 465 1.14±1.27 253 0.544
Pneumonia diagnosis
(secondary
outcome)
TT 1181 2772 2.24±2.16 62 0.022 −0.003 (−0.014–0.009) 0.899 (0.560–1.480)
DB 466 1044 2.35±2.00 26 0.025
OCS: oral corticosteroid; TT: triple therapy; DB: dual bronchodilation with long-acting muscarinic antagonist/long-acting inhaled β-agonist. #:
mean follow-up time in years available.
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results using the continuous modifiers. This was confirmed by the model fit statistics. The differences in
Akaike’s information criterion (AIC) and Bayesian information criterion (BIC), which take the number of
parameters introduced by categorical variables into account, show no evidence of better fit (lower AIC or
BIC) with the use of categorical variables (supplementary table 7).
The number of exacerbations in the baseline year showed significant effect modification with the primary
outcome (time to the first exacerbation) and with the secondary outcomes of time to the first acute
respiratory event and OCS course (figure 3a and supplementary table 8). The higher the exacerbation rate in
the baseline year, the greater the risk reduction for a future outcome in the TT initiators compared with the
DB initiators. After controlling for multiple testing, significant effect modification was found for the time to
the first acute respiratory event. The HR was 0.79 (95% CI 0.66–0.95) for patients with two exacerbations
compared with 0.19 (95% CI 0.04–0.87) for patients with five exacerbations in the baseline year.
The baseline BEC modified the effect of the comparison significantly for all time to the first event
outcomes, except time to the first antibiotics course (figure 3b and supplementary table 9). After
controlling for multiple testing, significant effect modification was found for the time to the first acute
OCS course prescribed. At a count <0.05×109 cells·L−1 the effect was in favour of DB (HR 1.24, 95% CI
1.01–1.53), and from a count of 0.35×109 cells·L−1 onwards TT showed a significantly greater
risk-reducing effect than DB.
The level of airflow limitation, GOLD risk group, and the number of nonrespiratory drugs prescribed did
not show significant effect modification with any of the study outcomes (supplementary figure 3).
Discussion
Our study shows that stepping-up from no prior maintenance therapy or LAMA monotherapy for COPD
to TT was associated with a greater reduction in the risk of exacerbation, acute respiratory event and
treatment failure than to a DB therapy in the study population. This association in favour of TT was
significantly greater for patients with higher rates of exacerbations in the year prior to step-up. TT was
also associated with a lower risk of outcome events than DB in patients with a higher BEC. However, we
did not find a significant difference in benefit from TT by GOLD severity and risk group. If this
observation is true, and not caused by limited power, this could be likely due to the existence of COPD
phenotypes with lower responsiveness within the higher risk GOLD group D. In both unadjusted IRR
analysis and multivariate outcome model analysis, rates of pneumonia in both treatment groups were
similar and not significantly different.
TABLE 5 Unadjusted and adjusted effects of triple therapy compared with dual bronchodilation
(baseline) on outcomes of interest during the outcome period
Outcome Patients Unadjusted Adjusted
HR (95% CI) p-value HR (95% CI) p-value
First exacerbation 1647 0.90 (0.79–1.02) 0.111 0.87 (0.76–0.99) 0.040
First acute respiratory event 1647 0.79 (0.70–0.88) <0.001* 0.74 (0.66–0.84) <0.001*
Treatment failure 1647 0.86 (0.76–0.98) 0.020 0.83 (0.73–0.95) 0.005*
First acute OCS course 1647 0.95 (0.82–1.09) 0.437 0.93 (0.80–1.07) 0.298
First antibiotics course 1647 0.91 (0.79–1.04) 0.171 0.89 (0.77–1.04) 0.138
Pneumonia diagnosis 1647 1.26 (0.80–1.98) 0.325 0.71 (0.21–2.38) 0.573
RR (95% CI) p-value RR (95% CI) p-value
Exacerbation rate 1138 0.85 (0.73–1.00) 0.056 0.86 (0.73–1.01) 0.068
Acute OCS courses rate 1138 0.83 (0.68–1.01) 0.067 0.80 (0.66–0.98) 0.030
Antibiotics courses rate 1138 0.88 (0.72–1.06) 0.183 0.91 (0.75–1.10) 0.332
Acute respiratory events rate 1138 0.80 (0.70–0.90) <0.001 0.79 (0.70–0.90) <0.001*
OR (95% CI) p-value RR (95% CI) p-value
mMRC ⩾2 885 1.20 (0.86–1.68) 0.293 1.12 (0.76–1.66) 0.566
HR: hazard ratio; OCS: oral corticosteroid; mMRC: modified Medical Research Council dyspnoea scale;
RR: rate ratio. *: p<0.05 after controlling for 10 statistical tests for secondary outcomes performed
following Holm’s method [22].
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FIGURE 3 a) Effect modification by number of exacerbations in the baseline year. b) Effect modification by
baseline blood eosinophil count. LAMA: long-acting muscarinic antagonist; LABA: long-acting inhaled β-agonist.
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Real-world evidence has been scarce on the comparative effectiveness of TT versus DB for COPD. Results
from two recently published RCTs showed significantly larger reduction in rate of exacerbations with TT
compared with DB therapy in selected COPD populations [9, 10]. There are however limitations inherent
to clinical trials. Participants are usually younger and not as severely ill as might be expected. Thus, they
are not fully representative of the real-world population the therapy would target. Also, different inclusion
and exclusion criteria are used for various clinical trials which complicates interpretation of data.
Therefore, it is important to supplement the findings of trials with evidence from observational studies.
Our timely real-world study complements and adds to the growing body of evidence in favour of TT for
some COPD patient populations.
A recent real-life study compared the treatment effectiveness of TT to DB using patients in the
DACCORD cohort [24]. In contrast to our study, they reported fewer exacerbations among patients who
received DB than TT. This might be due to the difference in patient population between both studies. Our
study includes patients with at least two exacerbations in the baseline year while >70% patients in
DACCORD had no exacerbation 6 months prior to study entry. As shown in the current study, patients
with higher baseline exacerbation have a greater benefit from TT. In addition, the previous study also
included patients who remained with their therapy, while we included patients who had no maintenance
therapy or only LAMA monotherapy at baseline.
Our study has many strengths. Firstly, we included only a population of patients who stepped-up to either
DB or TT and excluded patients with evidence of active asthma, asthma–COPD overlap syndrome, and
those prescribed the therapy under study at any point during the baseline year. Some RCTs have also
included patients in the DB group stepping down in their treatment from TT. The abrupt withdrawal of
ICSs during randomisation in these patients could have led to COPD exacerbations and thus exaggerated
the benefit of TT evident in the trial [10, 25, 26]. Secondly, we selected a homogeneous population of
patients who would be eligible for TT treatment according to GOLD recommendations, i.e. those who had
two or more exacerbations in the baseline year. Thirdly, we have examined effect modifiers to help identify
possible subgroups of patients that might benefit more from a treatment. In this study, patients with a
higher number of exacerbations in the baseline year and patients with a higher BEC had more benefit
from TT. Fourthly, the treatment groups we compared had well-balanced baseline characteristics after
matching and any residual measured confounding was accounted for in the analyses. Although we cannot
fully exclude residual bias by indication due to unmeasured characteristics, the risk of residual bias from
differences in COPD severity is likely to be small due to the availability of detailed information. Finally,
sensitivity analyses showed that restriction of the patient population during matching did not affect results
of time-to-event models. The exclusion of patients with a prior history of asthma gave similar results (or a
slightly stronger effect) meaning that the observed effects were not attributable to asthma.
Some limitations however also need consideration. We may have underestimated the relative effectiveness
of TT as we performed an intention-to-treat analysis without considering a step-up to TT in the DB group
during follow-up, which occurred in a third of patients. Also, our study was based only on multi-inhaler
TT whereas today, two fixed-dose single-inhaler TTs are available on the market [27], with a possible
benefit on adherence. On the other hand, 38.4% patients on DB were initiated on a single inhaler. Another
limitation of our study is that despite the large numbers of patients with COPD in the databases, we did
not achieve sufficient statistical power for analysing outcomes with low incident rates, such as pneumonia.
This is partly due to fact that DB has only recently been introduced as an alternative treatment option in
guidelines.
In conclusion, this real-world observational study found that TT was associated with a significantly greater
reduction in exacerbation risk and risk of other outcomes compared with DB in patients with a history of
at least two exacerbations in the previous year. The risk reduction effect for secondary outcomes, including
acute respiratory events and prescription of an acute OCS course, increased with prior exacerbation rate
and baseline BEC. Our results add to the emerging body of evidence in favour of TT over DB in patients
with frequent exacerbations in the management of COPD.
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